1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor. - Mezquita, L.; Xenophontos, E.; Pretzenbaher, Y.; Sureda, C.; Nadal, E.; Al-Rabi, K.; Rousseau Bussac, G.; Ponce Aix, S.; Sullivan, I.G.; Calles Blanco, A.; Cloarec, N.; De Langen, J.; et al. (Annals of Oncology, 2023)